Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $605.45M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 0.84M
Average 0.54M
Returns on capital
Bicara Therapeutics Inc. Common Stock management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-34.4%
avg 36.8%
ROIC
-38.6%
avg 36.8%
ROA
-32.0%
avg -157.7%
Analysis
ROA is currently the strongest return metric at -32.0% versus its period average of -157.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Claire Mazumdar Clemon | Chief Executive Officer & Director | USD 927.69K | 37 | — | — |
Ryan Cohlhepp | President, Chief Operating Officer & Director | USD 858.4K | 49 | 34.25K | 0.06% |
Angela Windt | Vice President & Head of Regulatory Affairs | — | — | — | — |
Jennifer Larson | CFO, Treasurer & Principal Accounting Officer | — | 51 | 0 | <0.01% |
Lara S. Meisner | Chief Legal Officer, Compliance Officer & Corporate Secretary | — | 54 | — | — |
Pauline Dufresne | Chief People Officer | — | — | — | — |
Rachel Frank | Vice President of Investor Relations and Corporate Communications | — | — | — | — |
Rachel Salazar | SVP of R&D Strategy and Operations | — | — | — | — |
Sathish Hasige | Senior Vice President and Head of Technical Operations & Supply Chain | — | — | — | — |
Jeltje Schulten | Senior Vice President of Clinical & Medical Affairs | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 8, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$4.80M
Sells
55
$9.12M
Net Transaction Value
−$4.32M
Net selling
Most Active
Cohlhepp Ryan
23 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 8, 26Sep 8, 2026 | Cohlhepp Ryan Direct | Sell | $80.7K$80,662.93 |
| Sep 8, 26Sep 8, 2026 | Cohlhepp Ryan Direct | Sell | $320.1K$320,052.86 |
| Aug 10, 26Aug 10, 2026 | Hyep Ivan Direct | Sell | $349.6K$349,591.25 |
| Aug 10, 26Aug 10, 2026 | Mazumdar Claire Direct | Sell | $279.8K$279,750.00 |
| Aug 10, 26Aug 10, 2026 | Cohlhepp Ryan Direct | Sell | $524.5K$524,533.13 |
| Jul 10, 26Jul 10, 2026 | Mazumdar Claire Direct | Sell | $831$831.04 |
| Jul 10, 26Jul 10, 2026 | Mazumdar Claire Direct | Sell | $283.4K$283,367.34 |
| Jul 9, 26Jul 9, 2026 | Cohlhepp Ryan Direct | Sell | $15.5K$15,544.00 |
| Jul 8, 26Jul 8, 2026 | Cohlhepp Ryan Direct | Sell | $656.7K$656,651.96 |
| Jul 8, 26Jul 8, 2026 | Cohlhepp Ryan Direct | Sell | $128.3K$128,302.01 |
1–10 of 57
Summary
Insiders reported 2 buys worth $4.80M and 55 sells worth $9.12M over the last 12 months. That adds up to net selling of $4.32M. Cohlhepp Ryan was the most active insider with 23 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Bicara Therapeutics Inc. Common Stock compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about BCAX's management, answered from reported figures.
Who manages BCAX?
Bicara Therapeutics Inc. Common Stock (BCAX) lists 10 active executives. The top listed executive is Angela Windt, Vice President & Head of Regulatory Affairs.
Are BCAX insiders buying or selling?
Recent insider activity shows net buying of $24.72M.
Continue the stock analysis
Jump to another research area for this company.